Online visual acuity test gains FDA clearance

Article

The web-based, self-guided software application is accessed through touchscreen mobile devices.

An online visual acuity test, the Visibly Digital Acuity Product (VDAP) (Visibly, Inc.), recently gained clearance from the Food and Drug Administration (FDA).1

The FDA described the VDAP as a web-based, self-guided software application that consumers can access using a touchscreen mobile device and internet-connected computer.

Adults aged 22 to 40 years who can perform an in-home self-test can use the test to help evaluate visual acuity, the FDA said.

According to the FDA website, “The application’s recommendations are intended to be supportive recommendations that will be used by an eye care provider, along with the patient’s medical history and profile, prior corrective eyewear prescriptions, and subjective vision data. This device does not provide screening or diagnosis of eye health or other disease and does not replace an eye health exam with a licensed provider.”

After the patient completes the test, the vision results are sent eye care professionals to evaluate and follow-up with the patient, for corrective lens prescription renewal online or referral for an in-person eye examination.

Reference
1. Larkin H. JAMA. Online visual acuity test cleared. 2022;328(13):1290. doi:10.1001/jama.2022.15443

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
© 2025 MJH Life Sciences

All rights reserved.